Skip to main content

Advertisement

SpringerLink
Log in

Differential Response to Medical Therapy for Male Lower Urinary Tract Symptoms

  • BPH-Related Voiding Dysfunction (R Lee, Section Editor)
  • Published:
Current Bladder Dysfunction Reports Aims and scope Submit manuscript

Abstract

Medical therapy has assumed a critical role in the treatment of male lower urinary tract symptoms (LUTS) secondary to bladder outlet obstruction. Targeting both bladder and prostate, these medications provide an effective means to manage LUTS for millions of men. However, significant proportion of men do not respond adequately to medical therapy and go on to surgical treatment of bladder outlet obstruction. In order to provide patients with appropriate therapy, prevent unnecessary exposure to drug side effects, and reduce medical costs, it is important to identify those men in whom medication will not be effective. In this review, we focus on the risk factors that predict failure of the common medical therapies for male LUTS. In addition, we describe recently discovered molecular targets that show promise for treatment of LUTS recalcitrant to conventional therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Bechis SK, Otsetov AG, Ge R, Olumi AF. Personalized medicine for the management of benign prostatic hyperplasia. J Urol. 2014;192:16–23. This is an extensive review of molecular pathophysiology and future therapies of BPH.

    Article  PubMed Central  PubMed  Google Scholar 

  2. Saigal CS, Joyce G. Economic costs of benign prostatic hyperplasia in the private sector. J Urol. 2005;173:1309–13.

    Article  PubMed  Google Scholar 

  3. Lepor H. Pathophysiology of lower urinary tract symptoms in the aging male population. Rev Urol. 2005;7 Suppl 7:S3–11.

    Google Scholar 

  4. Madersbacher S et al. EAU 2004 guidelines on assessment, therapy and follow-Up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol. 2004;46:547–54.

    Article  PubMed  Google Scholar 

  5. Oelke M et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64:118–40.

    Article  PubMed  Google Scholar 

  6. Michel MC, Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol. 2006;147 Suppl 2:S88–119.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Moriyama N et al. Detection of alpha 1-adrenoceptor subtypes in human hypertrophied prostate by in situ hybridization. Histochem J. 1996;28:283–8.

    Article  CAS  PubMed  Google Scholar 

  8. Roehrborn CG, Schwinn DA. Α1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol. 2004;171:1029–35.

    Article  CAS  PubMed  Google Scholar 

  9. Hampel C et al. Modulation of bladder α1-adrenergic receptor subtype expression by bladder outlet obstruction. J Urol. 2002;167:1513–21.

    Article  CAS  PubMed  Google Scholar 

  10. Ishihama H et al. Activation of α1D adrenergic receptors in the rat urothelium facilitates the micturition reflex. J Urol. 2006;175:358–64.

    Article  CAS  PubMed  Google Scholar 

  11. Smith MS, Schambra UB, Wilson KH, Page SO, Schwinn DA. α1-Adrenergic receptors in human spinal cord: specific localized expression of mRNA encoding α1-adrenergic receptor subtypes at four distinct levels. Mol Brain Res. 1999;63:254–61.

    Article  CAS  PubMed  Google Scholar 

  12. Chen QIN et al. Function of the lower urinary tract in mice lacking α1d-adrenoceptor. J Urol. 2005;174:370–4.

    Article  CAS  PubMed  Google Scholar 

  13. Koritsiadis G et al. Immunohistochemical estimation of hypoxia in human obstructed bladder and correlation with clinical variables. BJU Int. 2008;102:328–32.

    Article  PubMed  Google Scholar 

  14. Masuda H et al. Reactive oxygen species mediate detrusor overactivity via sensitization of afferent pathway in the bladder of anaesthetized rats. BJU Int. 2008;101:775–80.

    Article  CAS  PubMed  Google Scholar 

  15. Nomiya M et al. The effect of atherosclerosis-induced chronic bladder ischemia on bladder function in the rat. NeurourolUrodyn. 2012;31:195–200.

    CAS  Google Scholar 

  16. Ponholzer A, Temml C, Wehrberger C, Marszalek M, Madersbacher S. The association between vascular risk factors and lower urinary tract symptoms in both sexes. Eur Urol Platinum. 2006;50:581–6.

    Article  Google Scholar 

  17. Pinggera G-M et al. Association of lower urinary tract symptoms and chronic ischaemia of the lower urinary tract in elderly women and men: assessment using colour Doppler ultrasonography. BJU Int. 2008;102:470–4.

    Article  PubMed  Google Scholar 

  18. Djavan B, Chapple C, Milani S, Marberger M. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology. 2004;64:1081–8.

    Article  PubMed  Google Scholar 

  19. Michel MC, Mehlburger L, Bressel HU, Goepel M. Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms. Prostate Cancer Prostatic Dis. 1998;1:332–5.

    Article  CAS  PubMed  Google Scholar 

  20. Yucel M, Akin Y, Gulmez H, Ucar M. The effect of first dose of tamsulosin on flow rate and its predictive ability on the improvement of LUTS in men with BPH in the mid-term. Int Urol Nephrol. 2013;45:45. Study demonstrating urodynamic effect of initial tamsulosin dose.

    Article  PubMed  Google Scholar 

  21. Roehrborn CG. Three months’ treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate. Prostate Cancer Prostatic Dis. 2006;9:121–5.

    Article  CAS  PubMed  Google Scholar 

  22. Roehrborn CG et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol. 2008;179:616–21.

    Article  CAS  PubMed  Google Scholar 

  23. Roehrborn CG et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123–31.

    Article  PubMed  Google Scholar 

  24. Crawford ED et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol. 2006;175:1422–7. This post-hoc analysis of data from the MTOPS trial identified risk factors for BPH progression off medical therapy.

    Article  CAS  PubMed  Google Scholar 

  25. Hong K, Byun Y, Yoon H, Park Y, Chung W. Prospective factor analysis of alpha blocker monotherapy failure in benign prostatic hyperplasia. Kor J Urol. 2010;51:488–91.

    Article  Google Scholar 

  26. Hong SJ, Ko WJ, Kim SI, Chung BH. Identification of baseline clinical factors which predict medical treatment failure of benign prostatic hyperplasia: an observational cohort study. Eur Urol. 2003;44:94–100. This retrospective analysis examined the factors predicting BPH progression in patients receiving α1-blocker or combination α1-blocker/5α-reductase inhibitor therapy.

  27. Abrams P, Speakman M, Stott M, Arkell D, Pocock R. A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective & agr;1A-adrenoceptor antagonist*, in patients with benign prostatic obstruction. Br J Urol. 1997;80:587–96.

    Article  CAS  PubMed  Google Scholar 

  28. Lepor H et al. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol. 1992;148:1467–74.

    CAS  PubMed  Google Scholar 

  29. Takata R et al. Impact of four loci on serum tamsulosin hydrochloride concentration. Journal of human genetics. 2013;58:21–6. This interesting study attempted to identify genetic risk factors predicting failure of tamsulosin therapy.

    Article  CAS  PubMed  Google Scholar 

  30. Franco-Salinas G, de la Rosette JJMCH, Michel MC. Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations. Clin Pharmacokinet. 2010;49:177–88.

    Article  CAS  PubMed  Google Scholar 

  31. Loeb S et al. Prostate volume changes over time: results from the Baltimore longitudinal study of aging. J Urol. 2009;182:1458–62.

    Article  PubMed  Google Scholar 

  32. Cunha GR et al. Epithelial-mesenchymal interactions in prostatic development. I morphological observations of prostatic induction by urogenital sinus mesenchyme in epithelium of the adult rodent urinary bladder. J Cell Biol. 1983;96:1662–70.

    Article  CAS  PubMed  Google Scholar 

  33. Yang X et al. Differential expression of genes in co-cultured versus separately cultured fibroblasts and epithelial cells from human benign hyperplastic prostate tissues. Int J Mol Med. 2010;26:17–25.

    PubMed  Google Scholar 

  34. Powers GL, Marker PC. Recent advances in prostate development and links to prostatic diseases. Wiley Interdiscip Rev Syst Biol Med. 2013;5:243–56.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Bianchi S et al. Treatment of complicated benign prostatic hyperplasia with LHRH-analogues in aged patients. Int J Androl. 1989;12:104–9.

    Article  CAS  PubMed  Google Scholar 

  36. Russell DW, Wilson JD. Steroid 5 alpha-reductase: two genes/two enzymes. Annu Rev Biochem. 1994;63:25–61.

    Article  CAS  PubMed  Google Scholar 

  37. McConnell JD et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998;338:557–63.

    Article  CAS  PubMed  Google Scholar 

  38. Bruskewitz R et al. Effect of Finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group Proscar Long-Term Efficacy and Safety Study. Urology. 1999;54:670–8.

    Article  CAS  PubMed  Google Scholar 

  39. Tempany CM, Partin AW, Zerhouni EA, Zinreich SJ, Walsh PC. The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia. Prostate. 1993;22:39–42.

    Article  CAS  PubMed  Google Scholar 

  40. Roehrborn CG et al. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology. 1999;54:662–9.

    Article  CAS  PubMed  Google Scholar 

  41. Lukacs B, Grange JC, Comet D. One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice. Urology. 2000;55:540–6.

    Article  CAS  PubMed  Google Scholar 

  42. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology. 1996;48:398–405. A meta-analysis, which demonstrated that finasteride is most effective when prostate size > 40 mL.

    Article  CAS  PubMed  Google Scholar 

  43. Mishriki SF, Aboumarzouk O, Graham JT, Lam TB, Somani BK. Baseline symptom score and flow rate can predict failure of medical treatment of lower urinary tract symptoms: prospective 12-year follow-up study. Urology. 2013;81:390–4. A long-term follow up study examining risk factors for failure of BPH medical therapy.

    Article  PubMed  Google Scholar 

  44. Kaplan SA. Factors in predicting failure with medical therapy for BPH. Rev Urol. 2005;7 Suppl 7:S34–9.

    Google Scholar 

  45. Niu Y et al. Reduced levels of 5-alpha reductase 2 in adult prostate tissue and implications for BPH therapy. Prostate. 2011;71:1317–24. Initial study demonstrating methylation and differential expression of 5α-reductase in BPH tissue.

    CAS  PubMed  Google Scholar 

  46. Ge R et al. DNA methyl transferase 1 reduces expression of 5-alpha reductase 2 in the aging adult prostate. Am J Pathol (in press). 2014.

  47. Vignozzi L et al. Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells. J Endocrinol. 2012;214:31–43.

    Article  CAS  PubMed  Google Scholar 

  48. Fan Y et al. Low intraprostatic DHT promotes the infiltration of CD8+ T cells in BPH tissues via modulation of CCL5 secretion. Mediators Inflamm. 2014;2014:397815.

    Article  PubMed Central  PubMed  Google Scholar 

  49. Park DS, Shim JY. Histologic influence of doxazosin and finasteride in benign prostatic hyperplasia accompanying chronic inflammation. Urol Int. 2008;81:441–6.

    Article  CAS  PubMed  Google Scholar 

  50. Kim TB et al. Dutasteride, who is it more effective for? Second to fourth digit ratio and the relationship with prostate volume reduction by dutasteride treatment. BJU Int. 2012;110:E857–63.

    Article  CAS  PubMed  Google Scholar 

  51. Manning JT, Bundred PE, Newton DJ, Flanagan BF. The second to fourth digit ratio and variation in the androgen receptor gene. Evol Hum Behav. 2003;24:399–405.

    Article  Google Scholar 

  52. Mostaghel EA et al. Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention. Cancer Res. 2010;70:1286–95.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  53. Irwin DE et al. Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder. Eur Urol. 2009;56:14–20.

    Article  PubMed  Google Scholar 

  54. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol. 2006;49:651–8.

    Article  PubMed  Google Scholar 

  55. Steers WD. Pathophysiology of overactive bladder and urge urinary incontinence. Rev Urol. 2002;4 Suppl 4:S7–18.

    PubMed Central  PubMed  Google Scholar 

  56. Roosen A et al. A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol. 2009;56:810–9.

    Article  PubMed  Google Scholar 

  57. Sibley GN. The physiological response of the detrusor muscle to experimental bladder outflow obstruction in the pig. Br J Urol. 1987;60:332–6.

    Article  CAS  PubMed  Google Scholar 

  58. Kaplan SA et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006;296:2319–28. One of the large randomized controlled trials which demonstrated the safety and efficacy of antimuscarinics in management of male LUTS.

    Article  CAS  PubMed  Google Scholar 

  59. Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol. 2009;182:2825–30.

    Article  PubMed  Google Scholar 

  60. Yamaguchi O et al. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms—ASSIST, randomized controlled study. Urology. 2011;78:126–33.

    Article  PubMed  Google Scholar 

  61. Chapple C et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol. 2009;56:534–41.

    Article  CAS  PubMed  Google Scholar 

  62. Liao CH, Kuo YC, Kuo HC. Predictors of successful first-line antimuscarinic monotherapy in men with enlarged prostate and predominant storage symptoms. Urology. 2013;81:1030–3. A prospective study that identified high IPSS as a predictor of antimuscarinic success in treatment of male LUTS secondary to BOO.

    Article  PubMed  Google Scholar 

  63. Liao CH, Lin VC, Chung SD, Kuo HC. Therapeutic effect of alpha-blockers and antimuscarinics in male lower urinary tract symptoms based on the International Prostate Symptom Score subscore ratio. Int J Clin Pract. 2012;66:139–45.

    Article  CAS  PubMed  Google Scholar 

  64. Roehrborn CG et al. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. Eur Urol. 2009;55:472–9.

    Article  CAS  PubMed  Google Scholar 

  65. Roehrborn CG et al. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology. 2008;72:1061–7. Discussion 1067. A post-hoc analysis of the TIMES study demonstrating that a high PSA is associated with antimuscarinic failure in the treatment of male LUTS.

    Article  PubMed  Google Scholar 

  66. Hofner K, Burkart M, Jacob G, Jonas U. Symptomatic and quality of life response to tolterodine in subgroups of men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia. World J Urol. 2010;28:353–7.

    Article  CAS  PubMed  Google Scholar 

  67. Hsiao SM, Lin HH, Kuo HC. Factors associated with a better therapeutic effect of solifenacin in patients with overactive bladder syndrome. Neurourol Urodyn. 2014;33:331–4.

    Article  CAS  PubMed  Google Scholar 

  68. Hung SF, Chung SD, Kuo HC. Increased serum C-reactive protein level is associated with increased storage lower urinary tract symptoms in men with benign prostatic hyperplasia. PLoS One. 2014;9:e85588.

    Article  PubMed Central  PubMed  Google Scholar 

  69. Liu HT, Kuo HC. Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment. Urology. 2008;72:104–8. Discussion 108.

    Article  PubMed  Google Scholar 

  70. Liu HT, Lin H, Kuo HC. Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy. Neurourol Urodyn. 2011;30:1525–9.

    Article  PubMed  Google Scholar 

  71. Orita S et al. Inhibiting nerve growth factor or its receptors downregulates calcitonin gene-related peptide expression in rat lumbar dorsal root ganglia innervating injured intervertebral discs. J Orthop Res. 2010;28:1614–20.

    Article  CAS  PubMed  Google Scholar 

  72. Liu HT, Jiang YH, Kuo HC. Increased serum adipokines implicate chronic inflammation in the pathogenesis of overactive bladder syndrome refractory to antimuscarinic therapy. PLoS One. 2013;8:e76706.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  73. Rosen R et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44:637–49.

    Article  PubMed  Google Scholar 

  74. Bloch W et al. Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide. Prostate. 1997;33:1–8.

    Article  CAS  PubMed  Google Scholar 

  75. Lythgoe C, McVary KT. The use of PDE-5 inhibitors in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Curr Urol Rep. 2013;14:585–94.

    Article  PubMed  Google Scholar 

  76. Gacci M et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012;61:994–1003. A meta-analysis of randomized control trials of PDE-5 inhibitors in the treatment of male LUTS.

    Article  CAS  PubMed  Google Scholar 

  77. Fullhase C, Hakenberg O. New concepts for the treatment of male lower urinary tract symptoms. Curr Opin Urol. 2015;25:19–26.

    Article  PubMed  Google Scholar 

  78. Kitagawa Y et al. JTS-653 blocks afferent nerve firing and attenuates bladder overactivity without affecting normal voiding function. J Urol. 2013;189:1137–46.

    Article  CAS  PubMed  Google Scholar 

  79. Quiding H et al. TRPV1 antagonistic analgesic effect: a randomized study of AZD1386 in pain after third molar extraction. Pain. 2013;154:808–12.

    Article  CAS  PubMed  Google Scholar 

  80. Hedlund P. Cannabinoids and the endocannabinoid system in lower urinary tract function and dysfunction. Neurourol Urodyn. 2014;33:46–53.

    Article  CAS  PubMed  Google Scholar 

  81. Fullhase C et al. Spinal cord FAAH in normal micturition control and bladder overactivity in awake rats. J Urol. 2013;189:2364–70.

    Article  PubMed  Google Scholar 

  82. Gandaglia G et al. The fatty acid amide hydrolase inhibitor oleoyl ethyl amide counteracts bladder overactivity in female rats. Neurourol Urodyn. 2014;33:1251–8.

    Article  CAS  PubMed  Google Scholar 

  83. Li GL et al. Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects. Br J Clin Pharmacol. 2012;73:706–16.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  84. Huggins JP, Smart TS, Langman S, Taylor L, Young T. An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain. 2012;153:1837–46.

    Article  CAS  PubMed  Google Scholar 

  85. Fullhase C. et al. Reduction of obstruction related bladder overactivity by the guanylyl cyclase modulators BAY 41–2272 and BAY 60–2770 alone or in combination with a phosphodiesterase type 5 inhibitor. Neurourol Urodyn. 2014.

  86. Bonderman D et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation. 2013;128:502–11.

    Article  CAS  PubMed  Google Scholar 

  87. Erdmann E et al. Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. Eur Heart J. 2013;34:57–67.

    Article  CAS  PubMed  Google Scholar 

  88. Christ GJ, Andersson KE. Rho-kinase and effects of Rho-kinase inhibition on the lower urinary tract. Neurourol Urodyn. 2007;26:948–54.

    Article  CAS  PubMed  Google Scholar 

  89. White CW, Short JL, Ventura S. Rho kinase activation mediates adrenergic and cholinergic smooth muscle contractile responses in the mouse prostate gland. Eur J Pharmacol. 2013;721:313–21.

    Article  CAS  PubMed  Google Scholar 

  90. Masago T et al. Effect of the rho-kinase inhibitor hydroxyfasudil on bladder overactivity: an experimental rat model. Int J Urol. 2009;16:842–7.

    Article  CAS  PubMed  Google Scholar 

  91. Fukumoto Y et al. Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension. Circ J. 2013;77:2619–25.

    Article  CAS  PubMed  Google Scholar 

  92. Tanihara H et al. Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115. JAMA Ophthalmol. 2013;131:1288–95.

    Article  CAS  PubMed  Google Scholar 

  93. Cheng Y et al. Does adenosine triphosphate released into voided urodynamic fluid contribute to urgency signaling in women with bladder dysfunction? J Urol. 2010;183:1082–6.

    Article  CAS  PubMed  Google Scholar 

  94. Burnstock G. Purinergic signalling in the urinary tract in health and disease. Purinergic Signal. 2014;10:103–55.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  95. Cheng Y et al. ATP during early bladder stretch is important for urgency in detrusor overactivity patients. Biomed Res Int. 2014;2014:204604.

    PubMed Central  CAS  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Seth K. Bechis, Michelle M. Kim, Anton Wintner, and Evgeniy I. Kreydin declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Author notes

    Authors and Affiliations

    1. Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

      Seth K. Bechis, Michelle M. Kim, Anton Wintner & Evgeniy I. Kreydin

    Authors
    1. Seth K. Bechis
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Michelle M. Kim
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Anton Wintner
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Evgeniy I. Kreydin
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Evgeniy I. Kreydin.

    Additional information

    This article is part of the Topical Collection on BPH-Related Voiding Dysfunction

    Seth K. Bechis, Michelle M. Kim and Anton Wintner contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Bechis, S.K., Kim, M.M., Wintner, A. et al. Differential Response to Medical Therapy for Male Lower Urinary Tract Symptoms. Curr Bladder Dysfunct Rep 10, 177–185 (2015). https://doi.org/10.1007/s11884-015-0295-6

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s11884-015-0295-6

    Keywords

    Search

    Navigation